Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Fatostatin
Cat. No.:
OB0225LY-0010
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Fatostatin is a specific inhibitor of SREBP activation that impairs the activation of SREBP-1 and SREBP-2.
Synonym:
125256-00-0; Fatostatin A; 2-(2-Propylpyridin-4-yl)-4-(p-tolyl)thiazole; 4-(4-methylphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole; 4-[4-(4-Methylphenyl)-1,3-thiazol-2-yl]-2-propylpyridine; 4-(4-Methylphenyl)-2-(2-propyl-4-pyridinyl)thiazole; 2-(2-propyl-4-pyridyl)-4-(p-tolyl)thiazole; hydrobromide
CAS No.:
125256-00-0
Compound CID:
1889993
Formula:
C18H18N2S
Formula Weight:
294.41
Specification
Relative Density:
1.125 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Fatostatin can be used as an SREBP inhibitor in metabolic enzyme research and anti-tumor studies.
Library Information
Targets:
Metabolic enzymes
Receptors:
Fatty acid synthase; SREBP
Pathways:
Metabolism
Plate Number:
AOCL-1
Plate Location:
a11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
70 mg/mL; 237.76 mM
Ethanol Max Solubility:
70 mg/mL; 237.76 mM
Solubility:
Insoluble in water.
